Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 92-97

  Gotfried, Mark H ^a,b   Shaw, Jeng Pyng ^c   Benton, Bret M ^c   Krause, Kevin M ^c   Goldberg, Michael R ^c   Kitt, Michael M ^c   Barriere, Steven L ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DAPTOMYCIN; LUNG SURFACTANT; TELAVANCIN; VANCOMYCIN;

ABNORMAL LABORATORY RESULT; ADULT; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TOLERABILITY; FEMALE; FOAMY URINE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOKALEMIA; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG EPITHELIAL LINING FLUID; LUNG FLUID; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PAIN; POSTPROCEDURAL PAIN; PRIORITY JOURNAL; STEADY STATE; TASTE DISORDER; URINARY TRACT DISEASE;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG; MACROPHAGES, ALVEOLAR; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PULMONARY SURFACTANTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 37849002056     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00875-07     Document Type: Article

References (34)

1. Andrews, J. M., D. Honeybourne, G. Jevons, N. P. Brenwald, B. Cunningham, and R. Wise. 1997. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 40:573-577.
2. Baldwin, D. R., D. Honeybourne, and R. Wise. 1992. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob. Agents Chemother. 36:1176-1180.
3. Baldwin, D. R., D. Honeybourne, and R. Wise. 1992. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother. 36:1171-1175.
4. Baldwin, D. R., S. R. Maxwell, D. Honeybourne, J. M. Andrews, J. P. Ashby, and R. Wise. 1991. The penetration of cefpirome into the potential sites of pulmonary infection. J. Antimicrob. Chemother. 28:79-86.
5. Baldwin, D. R., R. Wise, J. M. Andrews, J. P. Ashby, and D. Honeybourne. 1990. Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3:886-890.
6. Baldwin, D. R., R. Wise, J. M. Andrews, and D. Honeybourne. 1991. Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax 46:658-662.
7. Barriere, S., F. Genter, E. Spencer, M. Kitt, D. Hoelscher, and J. Morganroth. 2004. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. 44:689-695.
8. Clinical and Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 6th ed. CLSI document M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Conte, J. E., Jr., J. Golden, S. Duncan, E. McKenna, E. Lin, and E. Zurlinden. 1996. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40:1617-1622.
10. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43:1329-1333.
11. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1995. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother. 39:334-338.
12. Conte, J. E., Jr., J. A. Golden, J. Kipps, and E. Zurlinden. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480.
13. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Baltimore, MD.
14. Gotfried, M. H., L. H. Danziger, and K. A. Rodvold. 2001. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114-1122.
15. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
16. LaFayette, A. J. 9 December 2004. Abbreviated validation to lower the range of a method for the determination of TD-6424 in human bronchial alveolar lavage fluid (BAL supernatant) by liquid chromatography and mass spectroscopy (LC/MS/MS) detection. Covance document 7057-234. Covance, Madison, WI.
17. LaFayette, A. J. 15 March 2006. Validation of a method for the determination of TD-6424 in human bronchial alveolar lavage fluid and alveolar macrophages by liquid chromatography and mass spectroscopy (LC/MS/MS) detection. Covance document 7057-212. Covance, Madison, WI.
18. LaFayette, A. J. 15 July 2004. Validation of a method for the determination of TD-6424, AMI-11352, and AMI-999 in human plasma by liquid chromatography and mass spectroscopy (LC/MS) detection. Covance document 7057-192. Covance, Madison, WI.
19. Laohavaleeson, S., J. L. Kuti, and D. P. Nicolau. 2007. Telavancin: a novel lipoglycopeptide for serious Gram-positive infections. Expert Opin. Investig. Drugs 16:347-357.
20. Mathai, D., M. T. Lewis, K. C. Kugler, M. A. Pfaller, R. N. Jones, and SENTRY Participants Group (North America). 2001. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn. Microbiol. Infect. Dis. 39:105-116.
21. Metropolitan Life Insurance Company. 1983. Metropolitan height and weight tables. Stat. Bull. Metrop. Life Insur. Co. 64:2-9.
22. Olsen, K. M., G. S. San Pedro, L. P. Gann, P. O. Gubbins, D. M. Halinski, and G. D. Campbell, Jr. 1996. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. 40:2582-2585.
23. Patel, K. B., D. Xuan, P. R. Tessier, J. H. Russomanno, R. Quintiliani, and C. H. Nightingale. 1996. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40:2375-2379.
24. Pennington, J. E. 1981. Penetration of antibiotics into respiratory secretions. Rev. Infect. Dis. 3:67-73.
25. Rennard, S. I., G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, P. G. Martin, and R. G. Crystal. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 60:532-538.
26. Reyes, N., R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner, and S. S. Hegde. 2005. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4344-4346.
27. Rodvold, K. A., L. H. Danziger, and M. H. Gotfried. 2003. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 47:2450-2457.
28. Rodvold, K. A., M. H. Gotfried, L. H. Danziger, and R. J. Servi. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399-1402.
29. Rodvold, K. A., M. H. Gotfried, J. S. Loutit, and S. B. Porter. 2004. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults, abstr. 0254. Clin. Microbiol. Infect. 10(Suppl. 3):44.
30. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
31. Silverman, J. A., L. I. Mortin, A. D. Vanpraagh, T. Li, and J. Alder. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. I. Infect. Dis. 191:2149-2152.
32. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallee, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey for the FAST 2 Investigator Group. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
33. Stryjewski, M. E., W. D. O'Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M. Vallee, V. G. Fowler, Jr., V. H. Chu, E. Spencer, S. L. Barriere, M. M. Kitt, C. H. Cabell, and G. R. Corey. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607.
34. Sun, H. K., K. Duchin, C. H. Nightingale, J.-P. Shaw, J. Seroogy, and D. P. Nicolau. 2006. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50:788-790.